--- title: "Erasca | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285991288.md" datetime: "2026-05-11T20:23:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285991288.md) - [en](https://longbridge.com/en/news/285991288.md) - [zh-HK](https://longbridge.com/zh-HK/news/285991288.md) --- # Erasca | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.6, missing the estimate of USD -0.2116. EBIT: As of FY2026 Q1, the actual value is USD -192.36 M. #### Net Loss Net loss for Erasca, Inc. was -$183.4 million for the three months ended March 31, 2026, a significant increase from -$31.0 million for the same period in 2025, representing an increase in net loss of -$152.5 million. #### Operating Expenses Total operating expenses amounted to $187.9 million for the three months ended March 31, 2026, compared to $35.6 million for the corresponding period in 2025. Loss from operations was -$187.9 million for the three months ended March 31, 2026, versus -$35.6 million for the same period in 2025. #### Research and Development (R&D) Expenses R&D expenses increased by $1.3 million to $27.3 million for the three months ended March 31, 2026, from $26.0 million in the prior year period. This increase was primarily due to a $1.7 million rise in personnel costs and a $1.0 million increase in clinical trials, preclinical studies, and discovery activities, partially offset by decreases of $1.1 million in outsourced services and $0.4 million in facilities-related expenses. **R&D Breakdown by Program (Three Months Ended March 31, 2026 vs. 2025)**: ERAS-0015: $13.8 million vs $6.5 million ERAS-4001: $6.7 million vs $4.0 million Other clinical programs (including naporafenib): $4.7 million vs $10.6 million Other discovery and preclinical programs: $2.1 million vs $4.8 million #### In-Process Research and Development (IPR&D) Expenses IPR&D expenses were $150.0 million for the three months ended March 31, 2026, compared to $0 for the same period in 2025, related to the expansion of a license agreement with Guangzhou Joyo Pharmatech Co., Ltd.. #### General and Administrative (G&A) Expenses G&A expenses rose by $1.0 million to $10.6 million for the three months ended March 31, 2026, from $9.7 million in the prior year, primarily due to a $0.9 million increase in personnel costs. #### Other Income (Expense), Net Total other income (expense), net, decreased by $0.2 million to $4.5 million for the three months ended March 31, 2026, from $4.7 million in the same period of 2025, mainly due to a decrease in interest earned. #### Cash, Cash Equivalents, and Marketable Securities As of March 31, 2026, Erasca, Inc. held $408.5 million in cash, cash equivalents, and marketable securities. #### Cash Flows from Operating Activities Net cash used in operating activities was -$27.4 million for the three months ended March 31, 2026, compared to -$31.6 million for the same period in 2025. The 2026 figure includes a net loss of -$183.4 million, changes in operating assets and liabilities of -$2.3 million, and accretion on marketable securities of -$0.7 million, partially offset by IPR&D expenses of $150.0 million, stock-based compensation expense of $8.5 million, and depreciation and amortization expense of $0.7 million. #### Cash Flows from Investing Activities Net cash used in investing activities was -$243.8 million for the three months ended March 31, 2026, a significant change from net cash provided of $34.3 million in the prior year. This increase in cash used was mainly driven by increases in purchases of marketable securities of $242.5 million and IPR&D of $150.0 million, partially offset by increases in sales of marketable securities of $100.8 million and maturities of marketable securities of $13.6 million. #### Cash Flows from Financing Activities Net cash provided by financing activities was $244.7 million for the three months ended March 31, 2026, compared to less than $0.1 million for the same period in 2025. This includes $242.7 million in net proceeds from a January 2026 common stock offering and $2.0 million from stock option exercises. #### Outlook and Strategy Erasca, Inc. expects its cash, cash equivalents, and marketable securities as of March 31, 2026, to fund operations into the second half of 2028. The company anticipates increased expenses and operating losses as it advances clinical trials and R&D, planning to finance future needs through equity offerings, debt, or collaborations. Its strategic focus remains on therapies for RAS/MAPK pathway-driven cancers, prioritizing its differentiated RAS-targeting franchise by ceasing naporafenib development. ### Related Stocks - [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md) ## Related News & Research - [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md) - [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)